MCC950

Synonyms: CP-456773, CRID3

MCC950 (CP-456773, CRID3) is a potent and selective inhibitor of NLRP3 (NOD-like receptor (NLR) family, pyrin domain-containing protein 3) with IC50 of 7.5 nM and 8.1 nM in BMDMs and HMDMs, respectively.

MCC950 Chemical Structure

MCC950 Chemical Structure

CAS: 210826-40-7

Selleck's MCC950 has been cited by 95 publications

Purity & Quality Control

Batch: Purity: 99.8%
99.8

Products often used together with MCC950

Rapamycin (Sirolimus)


MCC950 and Rapamycin mitigate clinical symptoms in experimental autoimmune encephalomyelitis (EAE) mice, promote autophagy, and reduce immunoinflammatory damage.

Xu L, et al. Life Sci. 2020 Jul 15;253:117747.

Metformin


MCC950 and Metformin exhibit complementary colonic protective effects by modulating HSP90/NLRP3 interactions and inducing autophagy in rats.

Saber S, et al. Inflammopharmacology. 2021 Feb;29(1):237-251.

Pramipexole


Administration of MCC950 and Pramipexole septic death in Pink1-/- and park2-/- mice.

Kang R, et al. Autophagy. 2016 Dec;12(12):2374-2385.

YQ128


MCC950 and YQ128 dose-dependently suppress the release of IL-1β from peritoneal macrophages upon LPS/ATP challenge.

Jiang Y, et al. J Med Chem. 2019 Nov 14;62(21):9718-9731.

Belnacasan (VX-765)


MCC950 and VX765 pretreatment abolishes the expression of GSDMD and the release of pro-inflammatory factors (IL-1beta, IL-18) in IPEC-J2 cells.

Mao X, et al. Toxicol Lett. 2023 Jan 1;372:25-35.

MCC950 Related Products

Choose Selective NLRP3 Inhibitors

Biological Activity

Description MCC950 (CP-456773, CRID3) is a potent and selective inhibitor of NLRP3 (NOD-like receptor (NLR) family, pyrin domain-containing protein 3) with IC50 of 7.5 nM and 8.1 nM in BMDMs and HMDMs, respectively.
Targets
NLRP3 [1]
(BMDM-based assay)
NLRP3 [1]
(HMDM-based assay)
7.5 nM 8.1 nM
In vitro
In vitro

MCC950 specifically inhibits NLPR3 inflammasome activation.[1]

Cell Research Cell lines NZM2328 podocyte cell line
Concentrations 1 µM
Incubation Time 24 h
Method

The NZM2328 podocyte cell line was stimulated with a control serum or a serum from diseased NZM2328 mice or serum from diseased NZM2328 mice depleted of IgG, with or without MCC950 or Mito TEMPO for 24 hours. After this incubation, cells were subjected to flow cytometry and Western blot analyses for NLRP3 inflammasome activation, mitochondrial membrane potential and production of reactive oxygen species (ROS) analysis.

(Data sourced from selleck products)

In Vivo
In vivo

Inhibition of NLRP3 with MCC950 ameliorates proteinuria, renal histological lesions and podocyte foot process effacement in lupus-prone mice.[1]

Animal Research Animal Models female NZM2328, a new NZM strain produced by extended backcrosses of NZB/WF1 to NZW mice
Dosages 10mg/kg
Administration i.p.

(Data sourced from selleck products)

Chemical Information & Solubility

Molecular Weight 404.48 Formula

C20H24N2O5S

CAS No. 210826-40-7 SDF --
Smiles CC(C)(C1=COC(=C1)S(=O)(=O)NC(=O)NC2=C3CCCC3=CC4=C2CCC4)O
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 80 mg/mL ( (197.78 mM); Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 5 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy MCC950 | MCC950 supplier | purchase MCC950 | MCC950 cost | MCC950 manufacturer | order MCC950 | MCC950 distributor